Loading cancer entity…
Loading cancer entity…
Clinical trials
6,746 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06361589 | Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients | recruiting | — | 200 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT06336954 | Adibelimab, Famitinib and Chemotherapy for Advanced NSCLC After PD-1 Inhibitor Failure | not yet recruiting | Phase 2 | 40 | Second Affiliated Hospital of Xi'an Jiaotong UniversityOTHER | 0 | Mar 29, 2024 |
| clinicaltrials |
| NCT06335355 | A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients | not yet recruiting | Phase 2 / Phase 3 | 401 | Shanghai Shengdi Pharmaceutical Co., LtdINDUSTRY | 1 | Mar 28, 2024 | clinicaltrials |
| NCT06329648 | Distributed Learning of Edic and CardIac Dose Effects in Lung Cancer(DECIDE) | not yet recruiting | — | 20,000 | The Netherlands Cancer InstituteOTHER | 0 | Mar 26, 2024 | clinicaltrials |
| NCT06225804 | A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK112 in Patients With Non-Small Cell Lung Cancer | recruiting | Phase 1 | 164 | Abbisko Therapeutics Co, LtdINDUSTRY | 2 | Mar 18, 2024 | clinicaltrials |
| NCT06020430 | Omitting CTV for Locally Advanced NSCLC Responded to Immunotherapy and Chemotherapy | recruiting | N/A | 134 | Hubei Cancer HospitalOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT06037733 | Primary Tumor Radiotherapy Omitting CTV for Patients With Advanced NSCLC Responded to Immunotherapy and Chemotherapy | recruiting | N/A | 134 | Hubei Cancer HospitalOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT05219734 | MRD Assay Evaluates Recurrence and Response Via a Tumor Informed Assessment(MARIA) | active not recruiting | — | 400 | Invitae CorporationINDUSTRY | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06053099 | A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19)(ROSIE) | recruiting | N/A | 300 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Mar 8, 2024 | clinicaltrials |
| NCT06297811 | Myeloprotection With Trilaciclib in Pan-cancer Population | not yet recruiting | Phase 2 | 132 | Sun Yat-sen UniversityOTHER | 1 | Mar 7, 2024 | clinicaltrials |
| NCT06299371 | Adebrelimab Plus Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC Harboring Driver Gene Mutations | not yet recruiting | Phase 2 | 36 | Liaoning Cancer Hospital & InstituteOTHER | 0 | Mar 7, 2024 | clinicaltrials |
| NCT04392505 | Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study(DART) | active not recruiting | Phase 2 | 100 | Oslo University HospitalOTHER | 4 | Feb 29, 2024 | clinicaltrials |
| NCT06282536 | Neoadjuvant Therapy With Iruplinalkib for Potentially Resectable ALK Positive NSCLC: A Single Arm, Exploratory Trial | not yet recruiting | Phase 2 | 20 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 0 | Feb 28, 2024 | clinicaltrials |
| NCT05332925 | Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC(TUMORIN) | recruiting | — | 25 | Jun Zhang, MD, PhDOTHER | 1 | Feb 23, 2024 | clinicaltrials |
| NCT05377658 | AK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung Cancer | recruiting | Phase 2 | 43 | Henan Cancer HospitalOTHER_GOV | 1 | Feb 21, 2024 | clinicaltrials |
| NCT05965024 | Exploration on the Value of MRD Based on ctDNA Detection in Predicting Recurrence of Resected Non-small Cell Lung Cancer | recruiting | — | 377 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Feb 21, 2024 | clinicaltrials |
| NCT06255197 | Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers | recruiting | — | 60,000 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 16, 2024 | clinicaltrials |
| NCT06241807 | Neoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB NSCLC | recruiting | Phase 2 | 30 | Shandong Cancer Hospital and InstituteOTHER | 1 | Feb 14, 2024 | clinicaltrials |
| NCT06254599 | A Study Of SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC | not yet recruiting | Phase 3 | 255 | Shouyao Holdings (Beijing) Co. LTDOTHER | 1 | Feb 12, 2024 | clinicaltrials |
| NCT04282044 | Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies | recruiting | Phase 1 | 60 | BioEclipse TherapeuticsINDUSTRY | 1 | Feb 8, 2024 | clinicaltrials |
| NCT05382728 | Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO) | recruiting | Phase 3 | 680 | TYK Medicines, IncINDUSTRY | 1 | Jan 30, 2024 | clinicaltrials |
| NCT06221462 | Neoadjuvant Sintilimab Plus Anlotinib Therapy in IB-IIIB Resectable Non-small Cell Lung Cancer(PRIORITY) | not yet recruiting | Phase 2 | 30 | Ningbo No.2 HospitalOTHER | 0 | Jan 25, 2024 | clinicaltrials |
| NCT06218940 | HY1272 in Patients With Locally Advanced or Metastatic Solid Tumors or Locally Advanced or Metastatic EGFRm+ NSCLC | not yet recruiting | Phase 1 | 40 | Newsoara Biopharma Co., Ltd.INDUSTRY | 0 | Jan 23, 2024 | clinicaltrials |
| NCT05011487 | Neoadjuvant Osimertinib + Chemotherapy for EGFR-mutant Stage III NSCLC(NOCE01) | recruiting | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Jan 16, 2024 | clinicaltrials |
| NCT05537701 | Tissue Eosinophils in Non-Small Cell Lung Cancer (the TEN Study)(TEN) | active not recruiting | — | 316 | Centre Hospitalier Universitaire de LiegeOTHER | 1 | Jan 16, 2024 | clinicaltrials |
| NCT06198868 | MRD-guided Prognosis Prediction and Adjuvant Treatment Based on CTC and ctDNA in NSCLC | recruiting | — | 60 | Jiangsu Cancer Institute & HospitalOTHER | 1 | Jan 12, 2024 | clinicaltrials |
| NCT06198907 | Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC)(JACKPOT33) | not yet recruiting | Phase 2 | 69 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 10, 2024 | clinicaltrials |
| NCT06188650 | The Efficacy and Safety of Drug Loaded Microsphere Bronchial Artery Chemoembolization (DEB-BACE) Combined With Anlotinib and Adebelimumab in the Third Line Treatment of Advanced NSCLC: a Prospective, Single Arm, Single Center, Exploratory Clinical Study | recruiting | N/A | 30 | Ningbo Medical Center Lihuili HospitalOTHER_GOV | 1 | Jan 3, 2024 | clinicaltrials |
| NCT06185400 | RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations | not yet recruiting | Phase 2 | 108 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Dec 29, 2023 | clinicaltrials |
| NCT06182761 | A Study of Sunvozertinib Combined With Anlotinib in Local Advanced or Metastatic Non-small Cell Lung Cancer(WUKONG-9) | not yet recruiting | Phase 2 | 45 | Shanghai Zhongshan HospitalOTHER | 0 | Dec 27, 2023 | clinicaltrials |
| NCT06109402 | Perioperative Immunotherpay Versus Adjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer | not yet recruiting | Phase 2 | 160 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Dec 19, 2023 | clinicaltrials |
| NCT05689619 | SILibinin in NSCLC and BC Patients With Single Brain METastasis (SILMET)(SILMET) | recruiting | N/A | 70 | A.O.U. Città della Salute e della ScienzaOTHER | 1 | Dec 15, 2023 | clinicaltrials |
| NCT06031181 | Sublobar Resection for Adenocarcinoma in Situ/Minimally Invasive Adenocarcinoma Diagnosed by Intraoperative Frozen Section (ECTOP-1019) | recruiting | Phase 3 | 390 | Fudan UniversityOTHER | 1 | Dec 13, 2023 | clinicaltrials |
| NCT03066297 | Optimal Extent of Pulmonary Resection in Clinical Stage IA Non-Small Cell Lung Cancer(OREX-IA) | active not recruiting | — | 1,018 | Samsung Medical CenterOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT04379739 | Neoadjuvant PD-1 Antibody Plus Apatinib or Chemotherapy for Non-small Cell Lung Cancer | active not recruiting | Phase 2 | 89 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT06147570 | A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer | recruiting | Phase 2 | 62 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 27, 2023 | clinicaltrials |
| NCT06142058 | RecistTM Criteria in Evaluating the Efficacy of Targeted Therapy for NSCLC | recruiting | — | 44 | Xueqin YangOTHER | 1 | Nov 21, 2023 | clinicaltrials |
| NCT06142617 | A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation. | not yet recruiting | Phase 2 | 37 | Peking Union Medical College HospitalOTHER | 1 | Nov 21, 2023 | clinicaltrials |
| NCT06127329 | Efficacy and Safety of BAI Combined With DEB-BACE of EqualSpheres in the Treatment of Advanced NSCLC | not yet recruiting | N/A | 70 | Gang WuOTHER | 1 | Nov 13, 2023 | clinicaltrials |
| NCT05344209 | Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Cancer(LUNGVAC) | recruiting | Phase 2 | 138 | Vestre Viken Hospital TrustOTHER | 1 | Nov 9, 2023 | clinicaltrials |
| NCT06117644 | The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLC | not yet recruiting | — | 30 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 0 | Nov 7, 2023 | clinicaltrials |
| NCT06116019 | Online Adaptive Radiotherapy Using a Novel Linear Accelerator (ETHOS)(ART-02) | recruiting | — | 649 | Charite University, Berlin, GermanyOTHER | 1 | Nov 3, 2023 | clinicaltrials |
| NCT05997719 | Exploring Cancer Evolution, Prognostic and Predictive Biomarkers in EGFR-mutant NSCLC | recruiting | — | 150 | Sun Yat-sen UniversityOTHER | 1 | Oct 24, 2023 | clinicaltrials |
| NCT05550961 | APOLLO 11, Consortium of Italian Centers Involved in Treatment of Patients With Lung Cancer Treated With Innovative Therapies: Real World Data and Translational Reaserch | recruiting | — | 1,200 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Oct 23, 2023 | clinicaltrials |
| NCT06092086 | Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC | recruiting | Phase 2 | 126 | Guangdong Association of Clinical TrialsOTHER | 1 | Oct 23, 2023 | clinicaltrials |
| NCT05988697 | Evaluate the Efficacy and Safety of Aspirin in Combination With Trametinib and Dabrafenib | not yet recruiting | — | 36 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 0 | Oct 12, 2023 | clinicaltrials |
| NCT06080776 | SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations | recruiting | Phase 3 | 242 | Nanjing Sanhome Pharmaceutical, Co., Ltd.INDUSTRY | 1 | Oct 12, 2023 | clinicaltrials |
| NCT05241028 | Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer | recruiting | Phase 2 | 80 | Hebei Medical University Fourth HospitalOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT05724004 | Alectinib Followed by Concomitant Consolidation Radiation Therapy in Advanced NSCLC With ALK-rearrangement (A-SAB)(A-SAB) | recruiting | N/A | 70 | Karolinska University HospitalOTHER | 1 | Oct 10, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Apr 12, 2024source: clinicaltrials